Core 4.0

C-PMI 1-5: Quality Management Program Evaluation

Submited by: Tom Goddard

The Basics

This standard both requires that your organization conduct an annual evaluation of the effectiveness of your QM program and describes the required components of that evaluation, which must be provided to the leadership at least annually. The required components include:

  • Recommendations to leadership on how to improve the QM program;
  • An analysis of the organization's performance as compared to the organization's goals for performance;
  • A finding of whether the staff and technical resources available for the QM program were sufficient;
  • Whether the people involved in the QM program were the right people to be involved; and
  • An impact assessment of the QM program.

Management Tips

First, we recommend that your report track the requirements of this standard. Clearly label each section of the evaluation report using language that corresponds closely to URAC's language, making it easier for the reviewer to recognize the report's compliance with the standard.
Second, keep in mind that this evaluation has, at its core, the underlying purpose of providing leadership with ideas that answer not only how the organization is doing in terms of QM but also what it should do in order to improve its performance. 
Impact, in this context, simply looks at the question of whether the QM program made a difference.

Accreditation Tips

Desktop Review
Submit your QM program description, a template of your QM program evaluation report, and meeting minutes demonstrating compliance with this standard. 
Validation Review
The URAC reviewer will talk with both leadership and QM staff about both the effectiveness of the program and how that effectiveness is evaluated.
Document review
The reviewer will examine QM evaluation reports, QMC meeting minutes, and other documentation of program evaluation.

  • Specialty Pharmacy 3.1 / 03.25.2019

    SDrM 6 - Patient Safety Process Requirements

    This standard requires that your pharmacy maintain a robust program for addressing patient safety issues. That program needs to have the capability of:Identification and reporting of adverse drug events;Reporting such events to external entities (e.g., payers, MedWatch, PSO);Identification and management of risk;Disclosing clinically significant errors to affected patients and their caregivers;Ide...

  • Specialty Pharmacy 3.1 / 03.25.2019

    SDrM 5 – Drug Utilization Management Reporting

    This brief standard simply requires that your pharmacy has a mechanism by which it provides a report on the drug utilization management program to the quality management committee ("QMC") or some other committee that oversees quality management.The content of that report is up to the pharmacy, but URAC has an expectation that it will include such information as:The volume of utilization reviews, s...

  • Specialty Pharmacy 3.1 / 03.25.2019

    SDrM 4 – Prospective, Concurrent, and Retrospective Drug Management

    If your pharmacy is contracted to conduct prospective, concurrent, and retrospective reviews, it must implement policies that such reviews involve a consideration of, where appropriate, the following issues:Therapeutic appropriateness; Over and underutilization;Generic use;Therapeutic interchange;Duplication;Drug-disease contraindications;Drug-drug or drug-allergy interactions; Drug dosage;Duratio...